Page 50 - 22-0424

The International Journal of the Royal Society of Thailand
Volume XI - 2019

Finkel R, Mercuri E, Darras B, Connolly A, Kuntz N, Kirschner J, et al. Nusinersen
versus sham control in infantile-onset spinal muscular atrophy. N Engl J
Med. 2017;377(18):1723–1732. doi:10.1056/NEJMoa1702752.

Finkel RS, Chiriboga C, Vajsar J, Day J, Montes J, De Vivo D, et al. Treatment of
infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-

label, dose escalation study. Lancet. 2016;388(10063):3017–3026. doi:10.1016/
S0140-6736(16)31408-8.
Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, et al.
Trial of galcanezumab in prevention of episodic cluster headache. N Engl
J Med. 2019;381:132–141. doi:10.1056/NEJMoa1813440.

Goemans NM, Tulinius M, van den Hauwe M, Kroksmark AK, Buyse G, Wilson
RJ, et al. Long-term efficacy, safety, and pharmacokinetics of drisapersen
in Duchenne muscular dystrophy: results from an open-label extension
study. PLoS One. 2016;11:e0161955. doi:10.1371/journal.pone.0161955.

Goyal N and Narayanaswami P. Making sense of antisense oligonucleotides:
A narrative review. Muscle Nerve. 2018;57: 356–370.doi:10.1002/mus.26001.

Harris R. Controversy continues over muscular dystrophy Drug, despite FDA
approval [Internet]. 2016 Sep 24 [cited 2019 June 12]. Available from:
https://www.npr.org/sections/health-shots/2016/09/24/495174472/
controversy-continues-over-muscular-dystrophy-drug-despite-fda-
approval

Korinthenberg R. A new era in the management of Duchenne muscular dystrophy.
Dev Med Child Neurol. 2019;61:292–297. doi:10.1111/dmcn.14129.

Lamberink H, Otte W, Geerts A, Pavlovic M, Ramos-Lizana J, Marson A, et al.
Individualised prediction model of seizure recurrence and long-term
outcomes after withdrawal of antiepileptic drugs in seizure-free patients:
a systematic review and individual participant data meta-analysis. Lancet
Neurol. 2017;16:523–531. doi:10.1016/S1474-4422(17)30114-X.

Levin AA. Treating disease at the RNS level with oligonucleotides. N Eng J Med.
2019;380:57–70. doi:10.1056/NEJMra1705346.

Lister Hill National Center for Biomedical Communications. U.S. National
Library of Medicine, National Institutes of Health, Department of Health

44 Precision Medicine in Neurological diseases

11/7/2565 BE 13:27
_22-0424(037-046)5.indd 44 11/7/2565 BE 13:27
_22-0424(037-046)5.indd 44